Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Syndax Pharmaceuticals (SNDX) EBITDA Margin (2016 - 2020)

Historic EBITDA Margin for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to 5226.32%.

  • Syndax Pharmaceuticals' EBITDA Margin fell 14881600.0% to 5226.32% in Q4 2020 from the same period last year, while for Dec 2020 it was 4708.17%, marking a year-over-year decrease of 9152300.0%. This contributed to the annual value of 1434.43% for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its EBITDA Margin stood at 5226.32% for Q4 2020, which was down 14881600.0% from 5238.26% recorded in Q3 2020.
  • Over the past 5 years, Syndax Pharmaceuticals' EBITDA Margin peaked at 1633.61% during Q4 2017, and registered a low of 5238.26% during Q3 2020.
  • Its 5-year average for EBITDA Margin is 4199.42%, with a median of 4327.19% in 2017.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' EBITDA Margin surged by 338655200bps in 2016, and later plummeted by -34540200bps in 2018.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' EBITDA Margin stood at 3652.79% in 2016, then skyrocketed by 55bps to 1633.61% in 2017, then crashed by -211bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then tumbled by -40bps to 5226.32% in 2020.
  • Its last three reported values are 5226.32% in Q4 2020, 5238.26% for Q3 2020, and 4382.59% during Q2 2020.